Canaan转发了
Thrilled to partner with Mariam Naficy and the entire Arcade team on their $25M Series A! This is the future of e-commerce as they combine AI with a unique supply chain to transform consumers into true creators.
Canaan
风险投资与私募股权管理人
San Francisco，California 19,581 位关注者
We’re an early-stage VC firm that invests in entrepreneurs with visionary ideas.
关于我们
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 33+ years. Canaan’s focus areas include Consumer Tech, Enterprise, Fintech, Frontier Tech and Life Sciences. To learn more about our people and our portfolio, please visit canaan.com.
- 网站
-
https://www.canaan.com
Canaan的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- San Francisco，California
- 类型
- 合营企业
- 创立
- 1987
- 领域
- Fintech、Enterprise SaaS、Digital Health、Biopharma Products & Platform、Medtech & Tools、Big Data /Cloud、Consumer、SaaS Security和Frontier Tech
地点
Canaan员工
动态
-
Pathios Therapeutics continues to build its leadership team in lockstep with its ongoing maturation.?Just four months after initiating its first-in-human clinical trial of its lead #GPR65 inhibitor, the company?has added a chief medical officer.?We're happy to see?Dr Sumeet Ambarkhane, MD join the Pathios C-suite and we're excited for the key contributions he'll make in guiding the development of the company's first-in-class GPR65 inhibitor, PTT-4256.?#immunooncology #cancer https://lnkd.in/eaKPBXwZ
-
With $35M of new funding in hand, the team at?Vivace Therapeutics, Inc. is full speed ahead on the clinical development of its first-in-class?#TEAD autopalmitoylation inhibitor, VT3989.?The company plans to move into a registrational Phase 3 trial in #mesothelioma and expects to meet with FDA later this year to discuss plans for the study.? With more than 150 patients already treated and evaluated as part of the ongoing Phase 1 trial, Vivace is the only company in the TEAD inhibitor space to report compelling #clinical activity.?This encouraging?efficacy is paired with an impressive safety and tolerability profile to position VT3989 as best-in-class. Importantly, the #Hippo pathway, which VT3989 targets, is implicated in a number of additional #cancer types beyond mesothelioma, offering the potential to impact the lives of more patients. We're proud to have participated in the company's Series D round and excited to follow its continued progress.?Canaan’s?own?Tim Shannon is a founding member of the Vivace board.?You can read more about the company and its Series D raise in today's press release. https://lnkd.in/e9pRkUcw
-
Canaan转发了
Consumer Tech is at an (exciting!) inflection point. Enjoyed sharing my thoughts (alongside Jason Fiedler, Meera Clark, and Matt Nugent and the full SVB research team). Check out the data driven report on how startups’ pursuit of profitability, capital scarcity, the emergence of AI and other key trends are impacting the consumer internet sector: https://lnkd.in/g5B_nXdv Renuka Kumar, CFA, Arianne Perry, Anjalika Komatireddy, Josh Pherigo
-
Alterome Therapeutics, Inc has kicked off a Phase 1/1b clinical study of ALTA3263 in adults with #KRAS mutant solid #tumors.?This morning, the company announced dosing of the first patient in this trial of the potential best-in-class oral KRAS-selective small molecule inhibitor.?We're excited to follow the program's progress.??Canaan's?Uwe Schoenbeck sits on the Alterome board.??https://lnkd.in/eW6BQufr
-
The sixth annual?Forbes Best Startup Employers 2025?list highlights?the top-performing startups based on employer reputation, employee satisfaction, and company growth. Congratulations to the Canaan-backed companies that made the list and stood out among thousands of startups: Diligent Robotics, Dragos, Inc., Dusty Robotics, Fireflies.ai, Lily AI, Roofstock, Snyk, and Tomorrow.io ?? Read more ??:?https://lnkd.in/dGSX3ahr
-
Early-stage founders are used to one constant: change. What matters most during uncertainty is a strong foundation and flawless execution of the fundamentals. Canaan’s Dana Malman Warren and Brendan Dickinson recently shared with?Fintech Nexus?how startups can navigate uncertainty, stay capital-efficient, and turn volatility into opportunity. Read more at https://lnkd.in/gJQ6tptz?
-
We're excited to back HeyMilo AI in building a more expansive and inclusive talent pool –?and a hiring process that’s faster, smarter, and more equitable. More from Rayfe Gaspar-Asaoka on why we invested: https://lnkd.in/gpiqwjZn
Excited to finally share this one! Sabashan Ragavan Ramie R. HeyMilo AI
-
Big milestone for Canaan portfolio company?Halda Therapeutics?with the dosing of the 1st patient in a Phase 1/2 clinical trial of HLD-0915.?The study will evaluate safety and tolerability when treating metastatic castration-resistant?#prostate?#cancer.?This is a big step in Halda's work advancing its novel small molecule?#RIPTAC?modality as a new cancer treatment approach. Canaan's own?Tim Shannon?chairs the company’s board. https://lnkd.in/eNC_yGHH
-
We're excited to back Valid on their mission to build the ad agency of the future ? ? Here's more from Jared Newman on why we invested: https://lnkd.in/g4hKGV_7
???I’m thrilled to announce Valid (formerly Validated) has raised a $5.5M seed round led by Canaan Partners, bringing our total funding to $7.3M. This fundraise includes participation from existing investors Neo and J Ventures, as well as investments from strategic investors including Steve Huffman (CEO of Reddit) and Scott Banister (inventor of search ads). With this injection of capital, we are accelerating our journey to build the infinitely scalable ad agency. The true potential of advertising remains untapped. 2% of GDP goes towards ads. Digital advertising generates the opportunity to place your business in front of the entire world. Strike the right keys, and scale infinitely. This promise remains unfulfilled. Today, 80% of advertising dollars flow through ad agencies. The deficiencies of these ad agencies are well known: they’re bloated, slow, and inefficient. Startup costs are high and performance is middling. It’s time for a new kind of ad agency— one that embraces technology and holds ROAS as its north star. ?????????? ??????????. Valid is the first AI-enabled ad agency, covering everything from attribution through ad delivery, leveraging technology to deliver results that are humanly impossible. Already, Valid has unlocked millions of dollars in revenue for dozens of mobile apps, B2B SaaS, and e-commerce customers. We think this is just the beginning. Our goal is for Valid to be around for 100 years, just like the best ad agencies. But unlike previous eras, we are not constrained by human bandwidth. With Valid, corner stores run ads as effectively as Nike. Ready to scale? Let’s connect: valid.co A special thank you to our many champions: Canaan (Jared Newman), JVentures (John Nordin), Neo (Ali Partovi & Suzanne Xie), Steve Huffman, Scott Banister, and Austen Allred. — For more details, see the link in the comments for our full post.